SRX Medicine

SRX Medicine / 2010 / Article

Clinical Study | Open Access

Volume 2010 |Article ID 326840 | https://doi.org/10.3814/2010/326840

Kohzo Takebayashi, Rika Naruse, Yoshimasa Aso, Toshihiko Inukai, "The Effect of Amlodipine on Oxidative Stress in Patients with Type 2 Diabetes", SRX Medicine, vol. 2010, Article ID 326840, 5 pages, 2010. https://doi.org/10.3814/2010/326840

The Effect of Amlodipine on Oxidative Stress in Patients with Type 2 Diabetes

Received02 Sep 2009
Revised07 Oct 2009
Accepted13 Oct 2009
Published13 Jan 2010

Abstract

Background. Amlodipine, a calcium channel blocker, is reported to have an antioxidative effect in vitro, but whether such an effect occurs clinically is unknown. The purpose of the study was to investigate the effect of amlodipine (5 mg/day) on oxidative stress by measuring urinary 8-iso-prostaglandin F2α (8-iso-PGF2α), an oxidative stress marker, in patients with type 2 diabetes. The anti-oxidative effect of amlodipine was also assessed using the levels of high-sensitivity C-reactive protein (hsCRP) and fibrinogen. Patients and Methods. Seventeen consecutive patients with type 2 diabetes complicated by hypertension were prospectively enrolled in the study. These patients received amlodipine (5 mg/day) over a 3-month period and various markers were measured before and at the end of this period. Results. Urinary 8-iso-PGF2α showed a tendency to decrease, but the change was not statistically significant (P=.1127). The patients were divided into two groups according to the baseline level of urinary 8-iso-PGF2α, and a significant decrease in 8-iso-PGF2α was found in the group (n=9) with a relatively high baseline 8-iso-PGF2α. There were no changes in hsCRP, fibrinogen, and plasminogen activator inhibitor-1. Significant decreases in systolic and diastolic blood pressure were observed (P<.0001, P=.0151, resp.). Conclusion. The results show that amlodipine (5 mg/day) may provide a clinically useful anti-oxidative effect, based on evaluation of urinary 8-iso-PGF2α.

References

  1. P. Libby, “Current concepts of the pathogenesis of the acute coronary syndromes,” Circulation, vol. 104, no. 3, pp. 365–372, 2001. View at: Google Scholar
  2. A. Warnholtz, G. Nickenig, E. Schulz et al., “Increased NADH-oxidase-mediated superoxide production. In the early stages of atherosclerosis evidence for involvement of the renin-angiotensin system,” Circulation, vol. 99, no. 15, pp. 2027–2033, 1999. View at: Google Scholar
  3. R. P. Mason, M. F. Walter, M. W. Trumbore, E. G. Olmstead Jr., and P. E. Mason, “Membrane antioxidant effects of the charged dihydropyridine calcium agonist amlodipine,” Journal of Molecular Cellular Cardiology, vol. 31, no. 11, pp. 275–281, 1999. View at: Google Scholar
  4. T. Yu, I. Morita, K. Shimokado, T. Iwai, and M. Yoshida, “Amlodipine modulates THP-1 cell adhesion to vascular endothelium via inhibition of protein kinase C signal transduction,” Hypertension, vol. 42, no. 3, pp. 329–334, 2003. View at: Publisher Site | Google Scholar
  5. C. Patrono and G. A. FitzGerald, “Isoprostanes: potential markers of oxidant stress in atherothrombotic disease,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 17, no. 11, pp. 2309–2315, 1997. View at: Google Scholar
  6. M. P. Reilly, D. Praticó, N. Delanty et al., “Increased formation of distinct F2 isoprostanes in hypercholesterolemia,” Circulation, vol. 98, no. 25, pp. 2822–2828, 1998. View at: Google Scholar
  7. K. Takebayashi, S. Matsumoto, Y. Aso, and T. Inukai, “Aldosterone blockade attenuates urinary monocyte chemoattractant protein-1 and oxidative stress in patients with type 2 diabetes complicated by diabetic nephropathy,” Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 6, pp. 2214–2217, 2006. View at: Publisher Site | Google Scholar
  8. H. Helmersson and S. Basu, “F2-isoprostane excretion rate and diurnal variation in human urine,” Prostaglandins Leukotrienes and Essential Fatty Acids, vol. 61, no. 3, pp. 203–205, 1999. View at: Publisher Site | Google Scholar
  9. K. Takebayashi, Y. Aso, and T. Inukai, “Initiation of insulin therapy reduces serum concentrations of high-sensitivity C-reactive protein in patients with type 2 diabetes,” Metabolism, vol. 53, no. 6, pp. 693–699, 2004. View at: Publisher Site | Google Scholar
  10. G. Davì, G. Ciabattoni, A. Consoli et al., “In vivo formation of 8-iso-prostaglandin and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation,” Circulation, vol. 99, no. 2, pp. 224–229, 1999. View at: Google Scholar
  11. J. Nourooz-Zadeh, J. Tajaddini-Sarmadi, S. McCarthy, D. J. Betteridge, and S. P. Wolff, “Elevated levels of authentic plasma hydroperoxides in NIDDM,” Diabetes, vol. 44, no. 9, pp. 1054–1058, 1995. View at: Google Scholar
  12. T. F. Luscher, R. R. Wenzel, P. Moreau, and H. Takese, “Vascular protective effects of ACE inhibitors ans calcium antagonists: theoretical basis for a combination therapy in hypertension and other cardiovascular disease,” Cardiovascular Drugs and Therapy, vol. 9, no. 8, supplement 3, pp. 509–523, 1995. View at: Google Scholar
  13. X. Zhang and T. H. Hintze, “Amlodipine releases nitric oxide from canine coronary microvessels: an unexpected mechanism of action of a calcium channel-blocking agent,” Circulation, vol. 97, no. 6, pp. 576–580, 1998. View at: Google Scholar
  14. K. Jamerson, M. A. Weber, G. L. Bakris et al., “Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients,” The New England Journal of Medicine, vol. 359, no. 23, pp. 2417–2428, 2008. View at: Publisher Site | Google Scholar

Copyright © 2010 Kohzo Takebayashi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder
Views233
Downloads0
Citations

Related articles